PT  - JOURNAL ARTICLE
AU  - Kevin J. Black
AU  - Mokhtar H. Gado
AU  - Joel S. Perlmutter
TI  - PET Measurement of Dopamine D<sub>2</sub> Receptor-Mediated Changes in Striatopallidal Function
AID  - 10.1523/JNEUROSCI.17-09-03168.1997
DP  - 1997 May 01
TA  - The Journal of Neuroscience
PG  - 3168--3177
VI  - 17
IP  - 9
4099  - http://www.jneurosci.org/content/17/9/3168.short
4100  - http://www.jneurosci.org/content/17/9/3168.full
SO  - J. Neurosci.1997 May 01; 17
AB  - This study was designed to validate an in vivomeasurement of the functional sensitivity of basal ganglia neuronal circuits containing dopamine D2 receptors. We hypothesized that a D2 agonist would decrease striatopallidal neuronal activity, and hence regional cerebral blood flow (rCBF) over the axon terminals in the globus pallidus. Quantitative pallidal blood flow was measured using positron emission tomography (PET) with bolus injections of H215O and arterial sampling in six baboons before and after intravenous administration of the selective D2 agonist U91356a. We also tested whether the response to U91356a was modified by previous acute administration of various antagonists. Another baboon had serial measurements of blood flow under identical conditions, but received no dopaminergic drugs. In all animals that received U91356a, pallidal flow decreased in a dose-related manner. Global CBF had a similar response, but the decline in pallidal flow was greater in magnitude and remained significant after accounting for the global effect. A D2 antagonist, but not antagonists of D1, serotonin-2, or peripheral D2 receptors, prevented this decrease. This work demonstrates and validates an in vivo measure of the sensitivity of D2-mediated basal ganglia pathways. It also supports the hypothesis that activation of the indirect striatopallidal pathway, previously demonstrated using nonselective D2-like agonists, can be mediated specifically by D2 receptors. We speculate that the U91356a-PET technique may prove useful in detecting functional abnormalities of D2-mediated dopaminergic function in diseases such as parkinsonism, dystonia, Tourette syndrome, or schizophrenia.